Delivery Order SPE2DB24D9238-SPE2DB25FDRAA
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its location in Park Ridge, IL. This delivery order was issued without a set-aside designation and carries an ultimate completion date of September 16, 2025. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency's Medical Supply Chain for the supply of Xolair 150 mg/ml syringes. The award, issued on August 29, 2025, with an ultimate completion date of September 22, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair syringes. This $1,547.40 firm fixed-price delivery order was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on the open market despite its small business status. Xolair...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at approximately $142,000 by the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 16, 2025, and was awarded on August 25, 2025, without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $18,568.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Xolair 150 mg/1.2 mL powder vials. This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 24, 2025, contains no set-aside designation. The contract represents a discrete fulfillment under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain issued a firm fixed-price delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml. The award was made on July 30, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the vendor's location in Park Ridge, Illinois. This delivery order carries no set-aside designation and represents a discrete purchase under DMS Pharmaceutical Group's larger indefinite delivery...
- The U.S. Defense Logistics Agency (DLA) awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $8,561.10 for XOLAIR 150 mg/ml. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion single-award vehicle valid through November 2026. The award carries no set-aside designation...
- The U.S. Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 MG/ML SYRINGEML. The potential value of the order is $1,547.42 with a completion date of February 26, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that provides a wide range of branded and generic pharmaceutical products to U.S. government agencies, particularly the...
- SPE2DB24D9238Indefinite Delivery Contract
- SPE2DB24D9238-SPE2DB25FDRAADelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,605.50 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, and the contract carries no set-aside designation. The delivery order is scheduled for completion by September 24, 2025, and represents a single purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA, valued at approximately $500 million and valid through November 2026. The supply of Xolair (omalizumab), a monoclonal antibody treatment used for moderate-to-severe allergic asthma and other allergic conditions, supports the medical supply needs of Department of Defense healthcare facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing delivery orders from DLA for an extensive portfolio of branded and generic pharmaceuticals, biologics, and medical consumables. This contract award reflects the company's ongoing role in providing specialized pharmaceutical products to military health facilities nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 9/3/25 |